Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market

FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.

More from Archive

More from Pink Sheet